南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2009年
11期
2284-2287
,共4页
贾卫东%邓西龙%唐小平%尹炽标%张复春%杨湛%方积乾
賈衛東%鄧西龍%唐小平%尹熾標%張複春%楊湛%方積乾
가위동%산서룡%당소평%윤치표%장복춘%양담%방적건
严重急性呼吸综合征%糖皮质激素%疗效%氧合指数%剂量
嚴重急性呼吸綜閤徵%糖皮質激素%療效%氧閤指數%劑量
엄중급성호흡종합정%당피질격소%료효%양합지수%제량
severe acute respiratory syndrome%glucocorticosteroids%therapeutic effect%oxygenation index%dose
目的 了解糖皮质激素(GCS)在SARS治疗中的应用概况,分析糖皮质激素应用剂量对改善肺氧合功能的影响.方法 回顾性研究2003年SARS病例225例,氧合指数(OD作为糖皮质激素疗效的判别指标,治疗有效的标准是治疗后OI较治疗前上升20%以上.结果 59.56%(134/225)的SARS病例在治疗过程中使用了糖皮质激素;所有病例糖皮质激素(静脉给药)治疗前OI的平均水平为237.08 mmHg,治疗后OI的平均水平为335.08 mmHg,平均升高110.26mmHg,升幅为46.41%;GCS每日体质量用量1~3mg/kg、每日用量160-240mg、累计用量1000~2000mg组的治疗效果最好;GCS应用疗程为8~14 d的治疗效果最好.结论 在SARS治疗中,适当应用糖皮质激素,对减轻患者肺部症状、改善肺功能有一定疗效.比较适宜的静脉给药方法为:每天用量1~3 mg/kg或160~240 mg/d,累计治疗8-14 d,累计用量控制在1500mg左右.
目的 瞭解糖皮質激素(GCS)在SARS治療中的應用概況,分析糖皮質激素應用劑量對改善肺氧閤功能的影響.方法 迴顧性研究2003年SARS病例225例,氧閤指數(OD作為糖皮質激素療效的判彆指標,治療有效的標準是治療後OI較治療前上升20%以上.結果 59.56%(134/225)的SARS病例在治療過程中使用瞭糖皮質激素;所有病例糖皮質激素(靜脈給藥)治療前OI的平均水平為237.08 mmHg,治療後OI的平均水平為335.08 mmHg,平均升高110.26mmHg,升幅為46.41%;GCS每日體質量用量1~3mg/kg、每日用量160-240mg、纍計用量1000~2000mg組的治療效果最好;GCS應用療程為8~14 d的治療效果最好.結論 在SARS治療中,適噹應用糖皮質激素,對減輕患者肺部癥狀、改善肺功能有一定療效.比較適宜的靜脈給藥方法為:每天用量1~3 mg/kg或160~240 mg/d,纍計治療8-14 d,纍計用量控製在1500mg左右.
목적 료해당피질격소(GCS)재SARS치료중적응용개황,분석당피질격소응용제량대개선폐양합공능적영향.방법 회고성연구2003년SARS병례225례,양합지수(OD작위당피질격소료효적판별지표,치료유효적표준시치료후OI교치료전상승20%이상.결과 59.56%(134/225)적SARS병례재치료과정중사용료당피질격소;소유병례당피질격소(정맥급약)치료전OI적평균수평위237.08 mmHg,치료후OI적평균수평위335.08 mmHg,평균승고110.26mmHg,승폭위46.41%;GCS매일체질량용량1~3mg/kg、매일용량160-240mg、루계용량1000~2000mg조적치료효과최호;GCS응용료정위8~14 d적치료효과최호.결론 재SARS치료중,괄당응용당피질격소,대감경환자폐부증상、개선폐공능유일정료효.비교괄의적정맥급약방법위:매천용량1~3 mg/kg혹160~240 mg/d,루계치료8-14 d,루계용량공제재1500mg좌우.
Objective To survey the dose of glucocorticosteroids administered in patients with severe acute respiratory syndrome (SARS) and assess the effect of glucocorticosteroid doses in improving the patients' lung function. Methods A retrospective analysis was conducted among 225 SARS patients treated in our in 2003. Oxygenation index was used as the effectless index, and the criteria for effectiveness was defiend as increase of the value of OI by 20% or above. Results Glococoticostecoids were used in 59.56% of the SARS cases. The average value of OI before intravenous use of glucocorticosteroids was 237.08 mmHg, and that after the administration was 335.08 mmHg. The glucocorticosteroid doses that produce better effects were 1-3 mg/kg and 160-240 mg daily, with the total accumulative dose of 1000-2000 mg. The optimal duration of glucocorticosteroid use was 8-14 days. Conclusions For SARS treatment, Glucocorticosteroids can effectively ameliorate the SARS patients' lung symptoms and improve the lung function. The appropriate daily dose of glucocorticosteroids is 1-3 mg/kg or 160-240 mg/d for a duration of 8-14 d; the accumulative dose should be controlled around 1500 mg.